Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.

Patients with metastatic triple-negative breast cancer (TNBC) have a poor prognosis. New approaches for the treatment of TNBC are needed to improve patient survival. The concept of synthetic lethality, brought about by inactivating complementary DNA repair pathways, has been proposed as a promising...

Full description

Bibliographic Details
Main Authors: Julie L Boerner, Nicole Nechiporchik, Kelly L Mueller, Lisa Polin, Lance Heilbrun, Scott A Boerner, Gina L Zoratti, Karri Stark, Patricia M LoRusso, Angelika Burger
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2015-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4361640?pdf=render
id doaj-4870bf194f7140bdb5a6912096e85e25
record_format Article
spelling doaj-4870bf194f7140bdb5a6912096e85e252020-11-25T02:47:04ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01103e011961410.1371/journal.pone.0119614Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.Julie L BoernerNicole NechiporchikKelly L MuellerLisa PolinLance HeilbrunScott A BoernerGina L ZorattiKarri StarkPatricia M LoRussoAngelika BurgerPatients with metastatic triple-negative breast cancer (TNBC) have a poor prognosis. New approaches for the treatment of TNBC are needed to improve patient survival. The concept of synthetic lethality, brought about by inactivating complementary DNA repair pathways, has been proposed as a promising therapeutic option for these tumors. The TNBC tumor type has been associated with BRCA mutations, and inhibitors of Poly (ADP-ribose) polymerase (PARP), a family of proteins that facilitates DNA repair, have been shown to effectively kill BRCA defective tumors by preventing cells from repairing DNA damage, leading to a loss of cell viability and clonogenic survival. Here we present preclinical efficacy results of combining the PARP inhibitor, ABT-888, with CPT-11, a topoisomerase I inhibitor. CPT-11 binds to topoisomerase I at the replication fork, creating a bulky adduct that is recognized as damaged DNA. When DNA damage was stimulated with CPT-11, protein expression of the nucleotide excision repair enzyme ERCC1 inversely correlated with cell viability, but not clonogenic survival. However, 4 out of the 6 TNBC cells were synergistically responsive by cell viability and 5 out of the 6 TNBC cells were synergistically responsive by clonogenic survival to the combination of ABT-888 and CPT-11. In vivo, the BRCA mutant cell line MX-1 treated with CPT-11 alone demonstrated significant decreased tumor growth; this decrease was enhanced further with the addition of ABT-888. Decrease in tumor growth correlated with an increase in double strand DNA breaks as measured by γ-H2AX phosphorylation. In summary, inhibiting two arms of the DNA repair pathway simultaneously in TNBC cell lines, independent of BRCA mutation status, resulted in un-repairable DNA damage and subsequent cell death.http://europepmc.org/articles/PMC4361640?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Julie L Boerner
Nicole Nechiporchik
Kelly L Mueller
Lisa Polin
Lance Heilbrun
Scott A Boerner
Gina L Zoratti
Karri Stark
Patricia M LoRusso
Angelika Burger
spellingShingle Julie L Boerner
Nicole Nechiporchik
Kelly L Mueller
Lisa Polin
Lance Heilbrun
Scott A Boerner
Gina L Zoratti
Karri Stark
Patricia M LoRusso
Angelika Burger
Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.
PLoS ONE
author_facet Julie L Boerner
Nicole Nechiporchik
Kelly L Mueller
Lisa Polin
Lance Heilbrun
Scott A Boerner
Gina L Zoratti
Karri Stark
Patricia M LoRusso
Angelika Burger
author_sort Julie L Boerner
title Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.
title_short Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.
title_full Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.
title_fullStr Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.
title_full_unstemmed Protein expression of DNA damage repair proteins dictates response to topoisomerase and PARP inhibitors in triple-negative breast cancer.
title_sort protein expression of dna damage repair proteins dictates response to topoisomerase and parp inhibitors in triple-negative breast cancer.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2015-01-01
description Patients with metastatic triple-negative breast cancer (TNBC) have a poor prognosis. New approaches for the treatment of TNBC are needed to improve patient survival. The concept of synthetic lethality, brought about by inactivating complementary DNA repair pathways, has been proposed as a promising therapeutic option for these tumors. The TNBC tumor type has been associated with BRCA mutations, and inhibitors of Poly (ADP-ribose) polymerase (PARP), a family of proteins that facilitates DNA repair, have been shown to effectively kill BRCA defective tumors by preventing cells from repairing DNA damage, leading to a loss of cell viability and clonogenic survival. Here we present preclinical efficacy results of combining the PARP inhibitor, ABT-888, with CPT-11, a topoisomerase I inhibitor. CPT-11 binds to topoisomerase I at the replication fork, creating a bulky adduct that is recognized as damaged DNA. When DNA damage was stimulated with CPT-11, protein expression of the nucleotide excision repair enzyme ERCC1 inversely correlated with cell viability, but not clonogenic survival. However, 4 out of the 6 TNBC cells were synergistically responsive by cell viability and 5 out of the 6 TNBC cells were synergistically responsive by clonogenic survival to the combination of ABT-888 and CPT-11. In vivo, the BRCA mutant cell line MX-1 treated with CPT-11 alone demonstrated significant decreased tumor growth; this decrease was enhanced further with the addition of ABT-888. Decrease in tumor growth correlated with an increase in double strand DNA breaks as measured by γ-H2AX phosphorylation. In summary, inhibiting two arms of the DNA repair pathway simultaneously in TNBC cell lines, independent of BRCA mutation status, resulted in un-repairable DNA damage and subsequent cell death.
url http://europepmc.org/articles/PMC4361640?pdf=render
work_keys_str_mv AT julielboerner proteinexpressionofdnadamagerepairproteinsdictatesresponsetotopoisomeraseandparpinhibitorsintriplenegativebreastcancer
AT nicolenechiporchik proteinexpressionofdnadamagerepairproteinsdictatesresponsetotopoisomeraseandparpinhibitorsintriplenegativebreastcancer
AT kellylmueller proteinexpressionofdnadamagerepairproteinsdictatesresponsetotopoisomeraseandparpinhibitorsintriplenegativebreastcancer
AT lisapolin proteinexpressionofdnadamagerepairproteinsdictatesresponsetotopoisomeraseandparpinhibitorsintriplenegativebreastcancer
AT lanceheilbrun proteinexpressionofdnadamagerepairproteinsdictatesresponsetotopoisomeraseandparpinhibitorsintriplenegativebreastcancer
AT scottaboerner proteinexpressionofdnadamagerepairproteinsdictatesresponsetotopoisomeraseandparpinhibitorsintriplenegativebreastcancer
AT ginalzoratti proteinexpressionofdnadamagerepairproteinsdictatesresponsetotopoisomeraseandparpinhibitorsintriplenegativebreastcancer
AT karristark proteinexpressionofdnadamagerepairproteinsdictatesresponsetotopoisomeraseandparpinhibitorsintriplenegativebreastcancer
AT patriciamlorusso proteinexpressionofdnadamagerepairproteinsdictatesresponsetotopoisomeraseandparpinhibitorsintriplenegativebreastcancer
AT angelikaburger proteinexpressionofdnadamagerepairproteinsdictatesresponsetotopoisomeraseandparpinhibitorsintriplenegativebreastcancer
_version_ 1724754852806918144